Top

World Journal of Surgery

Published in:

01-03-2011

Cost-Utility Estimation of Surgical Treatment of Pancreatic Carcinoma Aimed at Cure

Authors: David Ljungman, Kent Lundholm, Anders Hyltander

Published in: World Journal of Surgery | Issue 3/2011

Abstract

Background

Little is reported on costs for radical tumor resections of pancreatic carcinoma in relationship to adjusted quality of life survival postoperatively. Therefore, the aim of the present study was to estimate the cost utility of surgical treatment aimed at cure.

Methods

A population-based cohort of patients with exocrine or ampullary pancreatic adenocarcinoma resected for cure in Gothenburg University Hospitals during 1998–2005 were evaluated retrospectively (n = 139). Total inpatient and outpatient healthcare costs were available for 103 patients, and health-related quality of life (HRQL) (based on the SF-36 Health Survey) were assessed preoperatively and postoperataively in 119 patients. Survival and utility index (SF-36-6D) across 5 years of postoperative follow-up were used to achieve quality adjusted life years.

Results

Mean survival after resection was 977 days for patients with exocrine pancreatic carcinoma, with expected differences among subgroups as related to disease stage (p < 0.01), in agreement with international reports. The HRQL index was 0.65 ± 0.06 preoperatively, 0.63 ± 0.04 early postoperatively (<1 year) and 0.69 ± 0.06 at long-term follow-up (1–5 years) compared to 0.77 ± 0.02 in age-matched healthy reference individuals from the Swedish population (p < 0.05). Total lifetime costs for treatments including surgery and adjuvant chemotherapy were €39,000 per patient, with a mean of 1.13 (95% Confidence Interval [CI] 0.93–1.40) QALYs across 5 years follow-up. The cost per QALY was €35,000 (95% CI €28,026–€41,947).

Conclusions

Resection aimed at cure of pancreatic exocrine ductal carcinoma provided costs for one quality adjusted year of survival comparable to other complex surgical treatments within cost limits regarded as reasonable to bear by the Swedish health care system, as well as in several other Western countries.

Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96CrossRefPubMed

Bramhall SR, Allum WH, Jones AG et al (1995) Treatment and survival in 13, 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82:111–115CrossRefPubMed

Buchler MW, Wagner M, Schmied BM et al (2003) Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 138:1310–1314 discussion 1315CrossRefPubMed

Lillemoe KD, Yeo CJ, Cameron JL (2000) Pancreatic cancer: state-of-the-art care. CA Cancer J Clin 50:241–268CrossRefPubMed

Diener MK, Heukaufer C, Schwarzer G et al (2008) Pancreaticoduodenectomy (classic Whipple) versus pylorus-preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2:CD006053PubMed

Trede M, Schwall G, Saeger HD (1990) Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 211:447–458CrossRefPubMed

Nagakawa T, Sanada H, Inagaki M et al (2004) Long-term survivors after resection of carcinoma of the head of the pancreas: significance of histologically curative resection. J Hepatobiliary Pancreat Surg 11:402–408CrossRefPubMed

Carpelan-Holmstrom M, Nordling S, Pukkala E et al (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54:385–387CrossRefPubMed

Yeo CJ, Sohn TA, Cameron JL et al (1998) Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 227:821–831CrossRefPubMed

10.

Cleary SP, Gryfe R, Guindi M et al (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731CrossRefPubMed

11.

Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223:273–279CrossRefPubMed

12.

Ferrone CR, Brennan MF, Gonen M et al (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12:701–706CrossRefPubMed

13.

Kazanjian KK, Hines OJ, Duffy JP et al (2008) Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg 143:1166–1171CrossRefPubMed

14.

Andersson R, Vagianos C, Williamson R (2004) Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 6:5–12

15.

Du W, Touchette D, Vaitkevicius VK et al (2000) Cost analysis of pancreatic carcinoma treatment. Cancer 89:1917–1924CrossRefPubMed

16.

Hjelmgren J, Ceberg J, Persson U et al (2003) The cost of treating pancreatic cancer—a cohort study based on patients’ records from four hospitals in Sweden. Acta Oncol 42:218–226CrossRefPubMed

17.

Huang JJ, Yeo CJ, Sohn TA et al (2000) Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg 231:890–898CrossRefPubMed

18.

Kokoska ER, Stapleton DR, Virgo KS et al (1998) Quality of life measurements do not support palliative pancreatic cancer treatments. Int J Oncol 13:1323–1329PubMed

19.

Crippa S, Dominguez I, Rodriguez JR et al (2008) Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg 12:783–793 (discussion 793–784)CrossRefPubMed

20.

Schniewind B, Bestmann B, Kurdow R et al (2006) Bypass surgery versus palliative pancreaticoduodenectomy in patients with advanced ductal adenocarcinoma of the pancreatic head, with an emphasis on quality of life analyses. Ann Surg Oncol 13:1403–1411CrossRefPubMed

21.

Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB et al (2005) Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 92:471–477CrossRefPubMed

22.

Schniewind B, Bestmann B, Henne-Bruns D et al (2006) Quality of life after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head. Br J Surg 93:1099–1107CrossRefPubMed

23.

Esposito I, Friess H, Buchler MW (2001) Carcinogenesis of cancer of the papilla and ampulla: pathophysiological facts and molecular biological mechanisms. Langenbecks Arch Surg 386:163–171CrossRefPubMed

24.

Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13CrossRefPubMed

25.

Wente MN, Bassi C, Dervenis C et al (2007) Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 142:761–768CrossRefPubMed

26.

Wente MN, Veit JA, Bassi C et al (2007) Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 142:20–25CrossRefPubMed

27.

Raymond WA, Leong AS (1989) Immunoperoxidase staining in the detection of lymph node metastases in stage I breast cancer. Pathology 21:11–15CrossRefPubMed

28.

Amemiya K, Suzuki J, Kimura M (1986) Mechanism of action of pronase on chronic proliferative inflammation including granuloma angiogenesis in mice. Nippon Yakurigaku Zasshi 88:279–288CrossRefPubMed

29.

Hosch SB, Knoefel WT, Metz S et al (1997) Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. Pancreas 15:154–159CrossRefPubMed

30.

Hosch S, Kraus J, Scheunemann P et al (2000) Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res 60:6836–6840PubMed

31.

Ware JE Jr, Snow KK, Kolinski M et al (1993) SF-36 Health survey manual and interpretation guide. The Health Institute, New England Medical Center, Boston

32.

Sullivan M, Karlsson J, Ware JE Jr (1995) The Swedish SF-36 Health Survey-I. Evaluation of data quality, scaling assumptions, reliability, and construct validity across general populations in Sweden. Soc Sci Med 41:1349–1358CrossRefPubMed

33.

Brazier J, Usherwood T, Harper R et al (1998) Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 51:1115–1128CrossRefPubMed

34.

Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21:271–292CrossRefPubMed

35.

Kaplan RM (2002) Utility assessment for estimating quality-adjusted life years. In: Sloan FA (ed) Valuing health care. Costs, benefits, and effectiveness of pharmaceutical and other medical technologies. Cambridge University Press, New York

36.

Billingham LJ, Abrams KR (2002) Simultaneous analysis of quality of life and survival data. Stat Methods Med Res 11:25–48CrossRefPubMed

37.

Rindi G, Kloppel G (2004) Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 80(suppl 1):12–15CrossRefPubMed

38.

Winter JM, Cameron JL, Campbell KA et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10:1199–1210 (discussion 1210–1191)CrossRefPubMed

39.

Benassai G, Mastrorilli M, Mosella F et al (1999) Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res 18:23–28PubMed

40.

Talamonti MS, Small W Jr, Mulcahy MF et al (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13:150–158CrossRefPubMed

41.

Kurahara H, Takao S, Maemura K et al (2007) Impact of lymph node micrometastasis in patients with pancreatic head cancer. World J Surg 31:483–490 (discussion 491–482)CrossRefPubMed

42.

Hosch SB, Steffani KD, Scheunemann P et al (2002) Micrometastases from HBP malignancies and metastatic cancer. J Hepatobiliary Pancreat Surg 9:583–591CrossRefPubMed

43.

Tseng JF, Pisters PW, Lee JE et al (2007) The learning curve in pancreatic surgery. Surgery 141:694–701CrossRefPubMed

44.

Esposito I, Kleeff J, Bergmann F et al (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660CrossRefPubMed

45.

Tappenden P, Chilcott J, Ward S et al (2006) Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 42:2867–2875CrossRefPubMed

46.

Hwang JS, Tsauo JY, Wang JD (1996) Estimation of expected quality adjusted survival by cross-sectional survey. Stat Med 15:93–102CrossRefPubMed

47.

Matthews JN, Altman DG, Campbell MJ et al (1990) Analysis of serial measurements in medical research. BMJ 300:230–235CrossRefPubMed

48.

Earle CC, Chapman RH, Baker CS et al (2000) Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18:3302–3317PubMed

49.

Kontodimopoulos N, Niakas D (2008) An estimate of lifelong costs and QALYs in renal replacement therapy based on patients’ life expectancy. Health Policy 86:85–96PubMed

50.

Longworth L, Young T, Buxton MJ et al (2003) Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl 9:1295–1307CrossRefPubMed

51.

Clegg AJ, Colquitt J, Sidhu MK et al (2002) The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol Assess 6:1–153PubMed

52.

Henriksson M, Lundgren F, Carlsson P (2008) Cost-effectiveness of endarterectomy in patients with asymptomatic carotid artery stenosis. Br J Surg 95:714–720CrossRefPubMed

Title: Cost-Utility Estimation of Surgical Treatment of Pancreatic Carcinoma Aimed at Cure
Authors: David Ljungman
Kent Lundholm
Anders Hyltander
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 3/2011
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-010-0883-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cost-Utility Estimation of Surgical Treatment of Pancreatic Carcinoma Aimed at Cure

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2011

Mortality Associated with the Treatment of Gallstone Disease: A 10-Year Contemporary National Experience

Laparoscopic Repeat Resection of Recurrent Hepatocellular Carcinoma

Systematic Review of Prognostic Factors Related to Overall Survival in Patients with Stage IV Colorectal Cancer and Unresectable Metastases

Life, Liberty, and the Pursuit of Quality-adjusted Life-Years after Pancreatic Cancer Surgery

Gunshot Injuries in the Elderly: Patterns and Outcomes. A National Trauma Databank Analysis

Malignant Melanoma of the Skin: Long-term Follow-up and Time to First Recurrence